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Gastrointestinal stromal tumours (GIST), de-
spite being rare, pose a relevant medical problem
from the viewpoint of diagnosis and management.
GIST are fragile, liable to metastasise and often
located in delicate structures. Surgical options,
therefore, are limited. In the last decade an im-
proved understanding of the molecular mecha-
nisms of the disease has resulted in novel modes
of treatment. The introduction of systemic tyro-
sine kinase inhibitor therapy with imatinib has
significantly improved the outcome of the disease
and prolonged the survival of GIST patients. For
many patients the acute threat of a deadly cancer
has been transformed into a manageable chronic
condition. Drug safety, tolerability and compli-
ance, subjects of concern in all long-term thera-
pies, have proven to be acceptable for the tyrosine
kinase inhibitor imatinib. The present paper pro-
vides a compact overview of the epidemiology,
pathophysiology and morphology of GIST, with
special reference to the underlying molecular bi-
ology. Relevant aspects of diagnosis, therapy and
monitoring of the disease are reviewed with par-
ticular emphasis on the available clinical evidence
and recent guidelines.
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Summary
Historical aspects
While gastrointestinal stromal tumours
(GIST) are the most common mesenchymal neo-
plasm of the gastrointestinal tract, they have been
known as an entity characterised by a specific his-
tological and immunohistochemical pattern for
only ten years [1, 2]. After 1998 diagnoses of
GIST dramatically increased, most probably due
to improved histopathological detection and
greater awareness, but the true incidence may also
be rising [3]. As GIST are highly resistant to con-
ventional chemotherapy and radiotherapy [4–7],
and carry a high risk of metastatic relapse after
initial surgery [8], survival rates were poor until
2002 [9], when the FDA approved the tyrosine ki-
nase inhibitor (TKI) imatinib mesylate (formerly
STI571) for their treatment. Identification of
KIT receptor tyrosine kinase (KIT, CD117) ex-
pression in GIST in 1998 [10] and its precursor
cells, interstitial cells of Cajal, as well as the iden-
tification of gain-of-function mutations of KIT in
the vast majority of GIST [1], resulted in the in-
troduction in 2000 of imatinib mesylate as the
first effective systemic therapy for patients with
GIST [11]. Despite the substantial improvements
in survival and quality of life of patients with
GIST, primary and secondary resistance to ima-
tinib may occur. Accordingly, further research has
resulted in the introduction of an alternative ki-
nase inhibitor, sunitinib (formerly SU011248), as
second line therapy, and currently the efficacy of
nilotinib (formerly AMN107) is under investiga-
tion. But although systemic tyrosine kinase in-
hibitor has become established as the treatment of
GIST, it has not made surgery obsolete. Surgery
continues to be the standard treatment of lo-
calised resectable GIST. At present imatinib
treatment is under investigation in the adjuvant
and neo-adjuvant setting [12, 13].
The clinical significance of oncogenic KIT
and platelet derived growth factor alpha
(PDGFRα) mutations in gastrointestinal stromal
tumours has very recently been reviewed [14].An-
other recent review discussed the pathogenesis of
GIST, treatment strategies, mechanisms account-
ing for drug resistance and potential future per-
spectives [15].
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Epidemiology
In the past the incidence and prevalence
GIST were underestimated [16], until recent
population-based studies in Europe revealed an-
nual incidences of 10–20 per million and the
prevalence was estimated at 129 per million [17–
21].When stratified for risk according to tumour
size and proliferative index [22], Swedish data [17]
showed prevalence rates (per million) of 22 for
very low risk, 52 for low risk, 24 for intermediate
risk, 22 for high risk, and 9 for “overtly malig-
nant” GIST. The latter group included all pa-
tients with proven metastases at initial diagnosis
and accounted for 10% of the cohort (n = 288).
Recent studies suggest that very small (0.2–
10 mm) asymptomatic GIST are widespread in
the population and that mutations of the KIT
appear very early [23–25]. The majority of these
micro-GIST, however, do not progress to major
disease [23, 26].
GIST occur with about equal frequency in
men (54%) and women (46%) [16] and over a
wide age range, but about three quarters of symp-
tomatic GIST are diagnosed in patients aged over
50, with a median at 58 years [8]. In population-
based series, including cases diagnosed at autopsy,
the median age was some ten years older (66–69
years) [17, 18].
Carney triad [27], familial gastrointestinal
stromal tumour syndrome [28, 29], and von Reck-
linghausen syndrome are associated with an ele-
vated risk of developing GIST [30]. Specific asso-
ciations of GIST with other malignancies have
not been determined, but GIST are not infre-
quently seen with other neoplasms [31]. No risk
factors or causative factors have been identified.
GIST arise most commonly in the stomach
(50–65%) or small bowel (20–30%), although
they may occur anywhere along the gastrointesti-
nal tract [26]. The colon and rectum host some
5%–10%, and the oesophagus 5%, of GIST [8,
32]. GIST rarely develop in the mesentery, omen-
tum or retroperitoneum.
Guidelines
In 2006 the National Comprehensive Cancer
Network (NCCN) updated their clinical practice
guidelines on the management of patients with
GIST [33]. The ESMO Guidelines Working
Group approved clinical guidelines for diagnosis,
treatment and follow-up of GIST in 2006 [34]
and 2008 [35].The published guidelines partly di-
verge in their recommendations, and country-
specific health regulations may interfere with
their implementation, and so recommendations
specifically addressing the diagnosis and treat-
ment of GIST have recently been published in
Switzerland [36].
Histopathology and molecular biology
Morphological variants
Gastrointestinal stromal tumours are assumed
to derive from interstitial cells of Cajal or their
stem cell-like precursors [1, 2] comprising KIT
and KIT-ligand positive intermediates [37] be-
tween smooth muscle cells and the GI autonomic
nervous system [38, 39]. Most GIST can be classi-
fied histologically as spindle cell type (70–80%),
epithelioid type (20–30%) or mixed spindle and
epithelioid cell type (10%) [22, 40]. It has been
recognised that epithelioid cell type features
occur more often in tumours that originate in the
stomach, and further reports have already sug-
gested that the frequency of PDGFRA mutations
in epithelioid GIST may be higher than in spindle
cell variants [43, 49]. Yet the relevance of these
histological subtypes to underlying mutation,
prognosis, response to kinase inhibitor treatment,
progression-free and overall survival remains to
be investigated. Before the identification of spe-
cific and sensitive diagnostic markers the morpho-
logical diversity added to the diagnostic challenge.
Immunohistochemical markers of GIST in-
clude KIT (positive in 95% of cases), CD34 (60–
70%), and smooth muscle actin (30–40%, usually
focal and weak staining). KIT is established as the
most specific and sensitive diagnostic marker [10,
41].
Phenotypes
More than 95% of GIST express CD117,
irrespective of histological appearance, site of ori-
gin or biological behaviour, and CD117 is there-
fore considered to be the best feature for defini-
tion of GIST [22, 42], though it is no longer con-
sidered an absolute requirement for diagnosis
[43]. Usually at least 90% of cells in GIST show
CD117 immunostaining, but occasionally as few
as 5–20% have been reported [22].
The cell-cell adhesion glycoprotein CD34 is
expressed by 60–80% of GIST [22, 40], slightly
less by malignant [10] or small bowel GIST [44]
but consistently by rectal GIST [43].
Focal reactivity for smooth muscle actin is ex-
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hibited by 20–40% of GIST [22, 45], while posi-
tivity for the S100 protein and desmin are rare
(<5% and <2%, respectively) [22].
A new promising marker was recently discov-
ered on GIST, and was termed DOG-1. It appears
to be virtually absent in non-GIST and is ex-
pressed independently of mutation type [46, 47].
Experience is still limited as sensitive monoclonal
antibodies [47] are not yet universally available.
The expression of protein kinase C theta
(PKC
θ
) has been identified and found to be spe-
cific for GIST [48–52], but it has not been widely
adopted for routine diagnosis.
Immunostaining for platelet derived growth
factor alpha (PDGFRα) is not considered reliable
and quantitative data are scarce, although some
studies suggest its use as a diagnostic marker [53].
The KIT
Receptor tyrosine kinase
The c-KIT proto-oncogene located on chro-
mosome 4q11-21 encodes the CD117 protein
(c-KIT), a transmembrane receptor tyrosine kinase
signalling molecule. The protein contains an ex-
tracellular receptor for a growth factor termed
stem cell factor (SCF), mast cell growth factor or
steel factor, and continues via a transmembrane
domain to the intracellular tyrosine kinase moiety
(table 1) [54]. Tyrosine kinase is activated (au-
tophosphorylated) on dimerisation triggered by
the binding of SCF to two CD117 molecules, and
leads to the activation of further intracellular sig-
nalling cascades controlling cell proliferation, ad-
hesion and differentiation [55]. The functionally
important CD117 is expressed in mast cells,
haematopoietic stem cells, germ cells, some ep-
ithelial cells and the interstitial cells of Cajal [56].
Expression in other tumour types
Some tumour types, e.g., adenoid cystic carci-
noma, synovial sarcoma, rhabdomyosarcoma,
glioma, germinoma/seminoma, melanoma, an-
giosarcoma, acute myeloid leukaemia and masto-
cytosis can also express CD117 [41, 44]. Not
many of these occur within the gastrointestinal
tract, and by their overall clinicopathologic fea-
tures can hardly be mistaken for GIST [57]. Un-
usual CD117 staining is usually thought to be due
to technical artefact [22].
Mutations
Of the four different regions of KIT that have
been found to be mutated in GIST, the juxtamem-
brane part corresponding to exon 11 is most fre-
quently affected (table 1). Missense mutations in
KIT exon 11 are seen in 20–30% of GIST, and
when occurring in gastric GIST they seem to be
associated with a better prognosis [58, 59].
With a frequency of 5–13%, exon 9, encoding
the extracellular domain of KIT, is the second
most often mutated region of KIT and found al-
most exclusively in non-gastric intestinal GIST.
Much less frequent mutations occur in KIT exon
13, encoding the tyrosine kinase 1 domain (<1–
2%; Glu for Lys
642
), and appear to be associated
with higher malignancy of GIST [60, 61]. Muta-
tions of KIT exon 17 were observed in approx.
1% of GIST where substitutions of Lys or Tyr for
Asn
822
interfere with the phosphotransferase
domain (catalytic tyrosine kinase 2) [62]. There is
also anecdotal evidence of a kindred with both fa-
milial GISTs and mastocytosis that express a
germline KIT mutation in exon 8, resulting in
deletion of codon Asp
419
and affecting the extra-
cellular, juxtamembrane domain of KIT [63].
The underlying mechanism responsible for
the difference in dosing required from the muta-
tional status of the tumour (see later) is not
entirely understood. It is postulated that exon
KIT 9 Ala
501
-Tyr
502
duplications/insertions inter-
Frequency (Functional) domain Mutation type
c-KIT 80%
Exon 11 67% Juxtamembrane del, pm, ins, itd
Exon 9 10% Extracellular ins Ala
502
-Tyr
503
ins Phe
506
-Ala
507
-Phe
508
Exon 13 1–2% Intracellular tyrosine kinase 1 Glu for Lys
642
(P box, ATP and ADP binding sites, imatinib contact points) Lys for Glu
635
Exon 17 1% Intracellular tyrosine kinase 2 Lys for Asn
822
(DFG motif, imatinib contact point) Tyr for Asn
822
His for Asn
822
Exon 8 <1% Extracellular, juxtamembrane del Asp
419
PDGFRα 5–8%
Exon 18 5% Intracellular tyrosine kinase 2 Val for Asp
842
,
(DFG motif, imatinib contact point) Val for Asp
846
del
Exon 12 1% Juxtamembrane Val for Aspl
561
, del, ins
Exon 14 <1% Intracellular tyrosine kinase 1 Lys for Asn
659
(P box, ATP and ADP binding sites, imatinib contact points) Tyr for Asn
659
Table 1
Frequency, location
and type of muta-
tions in GIST, ordered
by frequency (del,
deletion; ins, inser-
tion; itc, internal tan-
dem duplication;
pm, point mutation)
adapted from Lasota
et al. 2008 [14].
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fere with an extracellular KIT antidimerisation
motif, resulting in spontaneous receptor homod-
imerisation [64]. These mutations seem to acti-
vate diverse intracellular signalling compared
with KIT exon 11 mutant tumours [65–67]. The
in vivo imatinib dose dependency of tumours ex-
pressing KIT exon 9 compared to exon 11 iso-
forms is even more intriguing, bearing in mind
that in vitro data show equal sensitivity to inhibi-
tion by imatinib [64]. The antitumour efficacy of
imatinib may be dependent not only on KIT inhi-
bition, but also on blockade of other kinases
which play a role in tumour growth.
The PDGFRα
Receptor tyrosine kinase
A homologous receptor tyrosine kinase to
KIT is platelet derived growth factor alpha
(PDGFRα) which is involved in connective tissue
growth and wound healing, but also expressed in
GIST [54]. Of the 20–25% of GIST without KIT
mutations, up to a third have mutations in
PDGFRα (table 1) [1, 68]. Most frequently af-
fected in 5% of cases is exon 18 with missense
mutations (Val for Asp
842
) or deletions [69]. This
exon encodes the tyrosine kinase 2 moiety, and the
mutations alter the activation loop that conforma-
tionally regulates the ATP-binding site [30]. In-
terestingly, PDGFRA mutations show a strong
predilection for gastric GISTs with epithelioid
morphology.These epithelioid GIST of the stom-
ach harbouring PDGFRαmutations seem to have
a favourable prognosis, whereas epithelioid GIST
occasionally found in the duodenum have been as-
sociated with a malignant behaviour [43].
Mutations
Mutations in exons 12 and 14 of PDGFRα
are rare (1% and <1%, respectively) and involve
substitutions, insertions and deletions (table 1)
[70, 71].
KIT und PDGFRα mutations are mutually
exclusive.
Patients Gender Age Tumour size Tumour site
no. (%) M/F ratio median (range) median (range) G D J C, R M, O
(years) (cm)
All 288 (100%) 1.0 69 (10–92) 7.0 (0.5–35.0) 170 13 84 18 3
Clinical- 199 (69%) 1.14 67 (10–92) 8.9 (1.0–35.0) 120 12 50 6 (C) 1 (M)
symptomatic 10 (R)
Clinical-incidental 60 (21%) 0.67 74 (42–89) 2.7 (0.5–10.0) 23 1 32 2 2 (O)
Autopsy-incidental 29 (10%) 0.93 78 (48–90) 3.4 (0.5–10.0) 27 0 2 0 0
Table 2
Clinical presentation
of GIST in the pre-
imatinib era accord-
ing to a population-
based study in Swe-
den [data from 17]
(G, stomach; D, duo-
denum; J, jejunum-
ileum; C, colon; R,
rectum; M, mesen-
terium; O, omentum).
Presenting symptoms and signs
About half of GIST are diagnosed in clinically
symptomatic patients. Two thirds of patients with
GIST present with often unspecific symptoms
due to an abdominal mass or tumour disruption,
such as dysphagia, obstruction, gastrointestinal
bleeding (with ensuing anaemia and its sequelae),
and/or abdominal pain. About a fifth of the tu-
mours are found incidentally at endoscopy, radio-
logical imaging or surgery for other reasons, and
approx. one tenth are incidentally discovered at
autopsy (table 2) [33].
GIST are most frequent in the elderly (me-
dian age at diagnosis in 288 Swedish patients:
69 years (table 2 and [17]), with only 25% diagnosed
at age 50 years or younger. Cases in patients under
30, including paediatric, are extremely rare (see
below).There is no predilection for either gender.
The tumours may form polypoid mucosal- or
serosal-based masses, but generally they are cen-
tred on the intestinal wall. GIST usually present
as single, well-circumscribed nodules (table 2 and
[30, 33]). The usual clinical manifestations of
GIST malignancy are liver metastases and/or
metastatic dissemination in the abdominal cavity
as innumerable serosal-based nodules. Metastasis
to lymph nodes, lung, bones and other extra-ab-
dominal sites, however, is extremely uncommon
[33].
Primary GIST range in size from less than
1 cm diameter, usually found incidentally, to more
than 35 cm, with a median at 50 mm [23, 33].
Paediatric GIST are very rare, occurring pre-
dominantly in female patients and associated with
gastric localisation and epithelioid morphology. In
general these tumours lack KIT and PDGFRα
mutations, suggesting an unrelated oncogenic
pathway. Recently, however, different mutations
(KIT exon 9 or PDGFRα exon 18) have been de-
scribed in paediatric GIST, but these mutations
may represent random mutagenic events [14].
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Long known and well established factors af-
fecting overall survival (OS) and progression- (or
disease-) free survival (PFS or DSF) of GIST pa-
tients are mitotic activity, measured in number of
mitoses per 50 high power fields (i.e., per 5 mm
2
,
mitotic index), and size of primary tumour. Apart
from these histological parameters, further clini-
copathological factors have recently been shown
also to affect OS and/or PFS, such as tumour lo-
cation [72], male sex, R1 resection or tumour rup-
ture, and, to a lesser degree, epithelioid cell or
mixed cell pathological subtype, also depending
on their localisation [73]. Analysis of two imatinib
trials (SWOG S0033 and EORTC 62005) by the
GIST Meta-Analysis Group (MetaGIST) involv-
ing data of 1640 patients followed up for a median
45 months has identified more prognostic para-
meters. Poor performance status (PS), high ab-
solute neutrophil count (ANC), absent exon-11
mutation and low baseline haemoglobin level were
significantly correlated with a lower PFS [74].
There is no specific staging or grading system
for GIST. Assessment of prognosis, i.e. the risk of
relapse or progression, is most commonly based
on tumour size and mitotic index of the primary
tumour (table 3) [22]. Extensions or adaptations
of this scheme have recently been published [75,
76]. Patients in the high risk strata have generally
been shown to be associated with increased dis-
ease recurrence and decreased survival [21, 75, 76]
despite complete surgical resection [77].
Another important risk factor in GIST is the
location of the tumour. It was shown in the pre-
imatinib era that small bowel stromal tumours
carry a higher risk of progression than gastric
stromal tumours of similar size and mitotic activ-
ity. Accordingly, risk assessment has recently been
refined by including the anatomic site of the re-
sected primary tumour (table 4) [33, 72]. In gen-
eral, GIST not exceeding 2 cm behave biologi-
cally in a non-aggressive manner (unless located
in the duodenum or rectum and showing more
than 5 mitoses per 50 high power fields), whereas
tumours larger than 2 cm have an increased risk
of recurrence. Other clinicopathologic factors,
such as PS, ANC, haemoglobin level and muta-
tional status should also be considered [74].
Prognostic factors and risk assessment
Risk group Mitotic index Tumour size
(counts per 50 HPF) (cm)
Very low <5 <2
Low <5 2–5
Intermediate 6–10 <5
<5 5–10
High >5 >5
Any >10
>10 Any
Resected metastases at diagnosis
Table 3
Risk stratification of
primary GIST accord-
ing to tumour size
and mitotic activity, a
consensus approach
2002 [22] (HPF, high
power field corre-
sponding to 5 mm
2
).
Tumour parameter Risk of progressive disease*
Mitotic index Size Gastric Duodenum Jejunum or Ileum Rectum
(counts per 50 HPF) (cm)
≤5 ≤2 None None None None
>2 ≤5 Very Low Low Low Low
>5 ≤10 Low Moderate n.a. n.a.
>10 Moderate High High High
>5 ≤2 None† High† n.a. High
>2 ≤5 Moderate High High High
>5 ≤10 High High n.a. n.a.
>10 High High High High
* defined as metastasis or tumour-related death; n.a. = not available (insufficient data); † small number of cases
Table 4
Risk assessment of
primary GIST consid-
ering anatomic site
in addition to size
and mitotic activity
[33]. Data based on
long-term follow-up
observation of 1939
patients [72] (HPF,
high power field
corresponding
to 5 mm
2
).
Treatment of GIST
Resectable GIST
Surgery
Surgery remains the mainstay treatment of lo-
calised resectable GIST [33, 78]. A complete gross
resection with preservation of an intact (pseudo-)
capsule and negative microscopic margins should
be the goal of surgery. Usually the resection can
be accomplished with a segmental resection of the
small intestine or a wedge resection of the stom-
ach. However, tumour size and location may
dictate more extensive surgery, including partial
or total gastrectomy. In the case of oesophageal,
duodenal and rectal GIST, wide resection is the
preferred treatment of choice [79]. Every effort
should be made to ascertain negative margins, al-
though wide margins have not been shown to be
beneficial [12]. The resection can be performed
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laparoscopically for small to intermediate size tu-
mours (<5 cm). In experienced hands minimally
invasive resections have recurrence rates similar
to open surgery and are associated with lower
morbidity and shorter hospital stays [80–82].
Lymphadenectomy is warranted only for evident
nodal involvement, since GIST rarely metastasise
to lymph nodes and haematological spread, usu-
ally into the liver, is the main route of GIST dis-
semination. Since GIST are fragile, they must be
handled with great care to avoid rupture and
probable intraabdominal dissemination, which
were shown to significantly shorten survival [6, 7].
For the same reason, preoperative percutaneous
biopsy is not recommended for tumours strongly
suspected to be GIST [83]. If performed at all,
this should be in centres of expertise. Tumours of
indeterminate type should be probed by endo-
scopic biopsy, or, if they are inaccessible by en-
doscopy, open biopsy should be chosen [84].
In approx. 85% of patients with localised pri-
mary GIST complete gross resection is achieved.
In 70–95% of these completely resected cases
negative microscopic margins are achieved. At
least 50% of patients experience tumour recur-
rence after complete resection, and 5-year sur-
vival is usually some 50% [77, 85, 86].
Neoadjuvant therapy
The preoperative use of imatinib is recom-
mended to avoid mutilating surgery [33, 36].
Neoadjuvant therapy aims at devitalising the
tumour mass, which should facilitate resection
(e.g., total gastrectomy, Whipple procedure).
The use of preoperative imatinib in potentially
resectable GIST is currently being tested in a
phase II trial by the US Radiation Therapy On-
cology Group (RTOG S-0132) and in a German
phase II trial (CSTI571-BDE43).
Careful response assessment under neoadju-
vant therapy is of particular concern. Early fusion
PET/CT scan may serve to identify patients not
responding to treatment who should be salvaged
by surgery. Most authors performed PET/CT
scans after one month of imatinib treatment. Re-
sponders should be operated on within 6–12
months of therapy. In patients with oesophageal
or rectal GIST surgery may be delayed for up to
one year, provided there is continuing response to
imatinib treatment [33].
Adjuvant therapy
Irrespective of the quality of the surgical pro-
cedure, recurrence occurs in a considerable num-
ber of patients after long term follow-up [72].
The 2007 update of the NCCN clinical practice
guidelines therefore suggests considering adju-
vant imatinib therapy [33]. Recent evidence sug-
gests that high risk patients with recurrent GIST
after complete resection could profit from adju-
vant imatinib [77]. Adjuvant imatinib is being
studied in major clinical trials (ACOSOG Z9000
and Z9001, Scandinavian/German SSG XVIII/
AIO, EORTC 62024).
Interim results in 107 patients of the
ACOSOG Adjuvant Trial (Z9000) indicate that
imatinib at 400 mg daily for 1 year following the
resection prolongs recurrence-free survival and is
associated with improved overall survival com-
pared to historical controls (99, 97 and 97% after
1, 2 and 3 years respectively). The 1, 2, and 3 year
recurrence-free survival rates were 94, 73, and
61% respectively. Half of the tumours were of
gastric origin and 42% arose in the small intes-
tine. Safety analysis showed adjuvant imatinib to
be well tolerated in this setting [87].
The ACOSOG Adjuvant Trial (Z9001)
showed that recurrence of GIST under adjuvant
imatinib treatment correlated with tumour size.
Patients were at considerably higher risk of recur-
rence when tumour size exceeded 10 cm. Com-
pared to placebo, the estimated relative risk for
tumour recurrence in patients receiving imatinib
Figure 1
Recurrence-free survival and primary tumour size after complete surgery and adjuvant
imatinib vs placebo for one year after resection. Z9001 interim data of 708 patients
[from 88] (size 3–6 cm: p = 0.15; size 6–10 cm: p = 0.01; size >10 cm: p <0.001).
3–6 cm Placebo (11 events)
3–6 cm Imatinib (4 events)
6–10 cm Placebo (21 events)
6–10 cm Imatinib (9 events)
>10 cm Placebo (30 events)
>10 cm Imatinib (8 events)
Years
Figure 2
Impact of the randomly allocated initial dose of imatinib on time to progression
in patients harbouring tumour with KIT exon 9 or 11 [data from 94].
Imatinib 800 mg/d, KIT exon 11
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at 400 mg daily was progressively lower with in-
creasing tumour size. Compared to placebo, ima-
tinib delayed recurrence in all tumour size strata
(fig. 1) (one year RFS: 97% vs 83%; p =0.0000014),
with adjuvant imatinib having greatest impact in
patients with larger tumours. The hazard ratio
(imatinib vs placebo) for patients with tumours
10 cm and larger was 0.19 (0.09–0.41; p <0.001),
for patients with tumours 6–10 cm 0.37 (0.17–
0.81; p <0.01) and, although not statistically sig-
nificant, 0.76 (0.17–3.4; p <0.15) for patients with
3–6 cm tumours. Overall survival was unchanged
[88].
A controlled randomised phase 3 trial is on-
going to investigate OS, relapse-free survival, re-
lapse-free interval, and safety in 900 patients re-
ceiving imatinib at 400 mg daily vs no further
therapy for two years after complete resection of
KIT positive GIST (EORTC 62024). Another
open-label, multicenter, prospective, randomized
phase III study in Scandinavia and Germany (SS-
GXVIII/AIO) investigates the efficacy and safety
of imatinib at 400 mg daily for either 12 or 36
months following macroscopically radical surgery
of GIST in patients estimated to be at a high risk
of disease recurrence. Accrual has recently been
closed at 400 patients.
On the basis of available data Swiss guidelines
recommend that patients at high and intermedi-
ate risk of recurrence (according to the Fletcher
criteria [22] and/or tumour location [72]) after re-
section of primary GIST enrol in prospective tri-
als of adjuvant imatinib and should be treated for
at least one year [36].
Figure 3
18
FDG-PET can detect imatinib response earlier than CT.
18
FDG-PET scans (A, C) and
a CT scan (E) with large tumour metastases in the liver one year after resection, before
the start of imatinib therapy.
18
FDG -PET (B, D) and CT (F) imaging evaluations after
two months of imatinib therapy. No pathological FDG uptake can be observed in the
liver. However, residual tumour on the CT scan remains considerable. From [110], with
permission from AlphaMed Press, 318 Blackwell Street, Suite 260, Durham, NC 27701,
U.S.A.
Non-resectable and/or metastatic GIST
Treatment options for patients with unre-
sectable or metastatic GIST were very limited in
the pre-TKI era, as GIST respond poorly to
chemotherapy or radiation therapy. Before the ad-
vent of imatinib median survival was 18–24
months [8, 89]. Today, as a general rule R1/R2 re-
sections and debulking or mutilating surgery are
no longer recommended and instead systemic
treatment with imatinib should be the standard
choice [33, 36]. The introduction of imatinib has
changed the natural history of the disease to the
extent that median survival after receiving diagno-
sis has increased to 4.8 years [33].
Standard dose imatinib
A long-term analysis of 147 imatinib-treated
patients with primarily unresectable or metastatic,
KIT expressing GIST, revealed that 52% of them
survived for more than five years [90] (phase II
study B2222 and extension). Partial response and
stable disease resulted in a similar survival benefit.
The study with a median follow-up of 63 months
and longer also showed that long-term imatinib
treatment was well tolerated and that a daily dose
of 600 mg was not superior to standard 400 mg
[91].
High dose imatinib
An imatinib starting dose of 400 mg or
800 mg daily was compared in studies EORTC
62005 and SWOG S0033 with the option of
crossover to the higher dose regimen upon pro-
gression at the lower dose [92, 93]. The analysis
included 1640 patients with a median follow-up of
42 and 55 months (EORTC and SWOG respec-
tively), for almost half of which mutation data
were available. Patients progressing on imatinib at
400 mg per day significantly benefited from cross-
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ing over to 800 mg imatinib per day. In both trials
response rates and PFS did not differ significantly
between the two initial dosing arms [74].
Subgroup post-hoc analyses of the combined
data of the EORTC 62005 and the SWOG S0033
studies (Meta-GIST) showed that patients with a
GIST harbouring a KIT exon 9 mutation had a
significant PFS benefit from starting with ima-
tinib 800 mg per day as compared to 400 mg per
day (HR 0,89). For KIT exon 11 carriers the
higher dose advantage is less significant (fig. 2).
There was no evidence of prolonged overall sur-
vival [74, 94]. Based on these analyses the ESMO
clinical guidelines and the Swiss guidelines rec-
ommend 800 mg as the starting dose for patients
harbouring an exon 9 mutation [35, 36].
Duration imatinib therapy
The French phase III trial BFR14 ran-
domised 58 patients with metastatic or unre-
sectable GIST after one year of tumour control
on treatment with 400 mg imatinib daily to con-
tinue or stop treatment. Patients whose imatinib
therapy was interrupted had a significantly higher
risk of relapse (p <0.0001) [95]. These findings
were confirmed after three years of tumour con-
trol in 35 patients [96]. No differences in overall
survival or imatinib resistance were observed be-
tween the two arms. Although more than 92%
(after one year, 100% after three years) of the pa-
tients with disease progression after interruption
responded to the reintroduction of imatinib treat-
ment [95, 96], Swiss guidelines discourage inter-
ruption of treatment outside of a clinical trial, un-
less progression, intolerance or patient refusal oc-
curs [36].
Management of progression
Under prolonged TKI treatment in patients
with advanced GIST the risk of resistance to ther-
apy is elevated [97]. An increasing frequency of
secondary mutations in KIT or PDGFRα has
been reported [98, 99]. While metastases usually
carry the primary mutations and continue to re-
spond to TKI therapy, clones of new additional
KIT mutations (rarely PDGFRα mutations) are
found in a proportion of several lesions [99].
Polyclonal resistance is indicated by the presence
of several different new mutations, as reported in
chronic myelogenous leukaemia under imatinib
therapy [100]. Secondary mutations are missense
mutations and are largely located in the kinase
domains (KIT exons 13–17) [14] of the same al-
lele to the primary mutations [101]. GIST with
secondary mutations in exon 13 and 14 were re-
ported to be sensitive to sunitinib [14]. Surgical
resection of the lesions with acquired resistance
may be indicated [102, 103], while still respond-
ing tumour masses would not need surgical inter-
vention during an ongoing TKI regimen.
A correlation between plasma imatinib levels
and clinical benefit was recently reported. Pa-
tients of the B2222 study with plasma imatinib
levels above 1100 ng/ml showed significantly
longer time to progression (TTP) compared to
patients with lower plasma imatinib levels (me-
dian TTP 30.6 vs 11.3 months; p = 0.0029) [90].
As the pre-existing tumour tissue continues to re-
spond to imatinib, escalation of the imatinib dose
regimen can slow the growth of the resistant le-
sions [104]. In the event of disease progression
Swiss guidelines recommend to checking plasma
imatinib levels and considering a dose escalation
to 800 mg per day [36]. But now patient adher-
ence to treatment is also an important issue that
should not be ignored, with up to 30% of patients
stopping taking their pills [105].
After disease progression on high dose ima-
tinib or imatinib intolerance, switching to sec-
ond-line therapy with sunitinib may be successful
[89]. The effectiveness of sunitinib could depend
on the mutational status, as wild-type or KIT
exon 9 mutants have shown a better response than
KIT exon 11 mutants. Close monitoring for ad-
verse effects of sunitinib is mandatory. The ap-
proved schedule for sunitinib is 50 mg per day for
four weeks followed by a two-week rest, although
continuous administration of 37.5 mg per day has
proved equally effective and better tolerated
[106]. The latter administration schedule may
also avoid tumour regrowth in the off-treatment
interval. The continuous regimen is recom-
mended in Switzerland [36].
In the event of localised progression invasive
therapeutic options, such as surgery or radiofre-
quency ablation, may be considered for selected
patients [33].
Imaging and monitoring
CT and PET scan
Although abdominal computed tomography
(CT) is considered the imaging method of choice
for treatment monitoring and staging of GIST,
positron emission tomography (PET) is a valuable
complementary tool. CT is recommended for ini-
tial abdominal imaging as well as surveillance of
metastatic disease after surgical resection of GIST
and monitoring of systemic therapy. NCCN
guidelines recommend CT within three months of
initiating TKI therapy, to be repeated every 3–6
months. The 2008 ESMO guidelines maintain
that risk assessment based on mitotic count, tu-
mour size and tumour site may help in choosing
the routine follow-up policy, but leave it to the
discretion of the institution to choose a routine
follow-up scheme with CT. Intermediate and
high-risk patients could, for example, undergo a
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routine follow-up with CT scan every 3–4
months for 3 years, then every 6 months up to 5
years, and yearly afterwards; for low-risk tumours
follow-up could be carried out with CT scan
every 6 months for 5 years. The 2008 ESMO
guidelines also state that very low risk GIST
probably do not deserve routine follow-up, al-
though one must be aware that the risk is not nil
[35]. As imatinib therapy may “unmask” small he-
patic metastases not seen on baseline CT scans,
their appearance should not be misinterpreted as
emergence of new foci of progressive disease. Tu-
mour size-based assessment of GIST stage should
be applied cautiously, as an apparent increase in
tumour mass may be due to intratumoral haemor-
rhage caused by treatment response [33, 78].
Some of these pitfalls may be avoided by PET
functional imaging. The use of whole-body 18F-
2-fluoro-2-deoxy-D-glucose PET (
18
FDG-PET)
appears limited for staging of GIST due to the
low rate of extra-abdominal tumoural involve-
ment and lower sensitivity than CT.
18
FDG-PET
may still be useful, particularly when morpholog-
ical findings are ambiguous, treatment efficacy is
uncertain or the CT scan indicates disease pro-
gression, especially when these findings disagree
with clinical data. In combination with CT,
18
FDG-PET allows detection of otherwise incon-
spicuous metastatic sites, early confirmation of
treatment response (fig. 3) and also detection of
resistance to TKI treatment. Response to
imatinib can be seen as early as 24 hours after
administration of a single dose [107] and is prog-
nostic, i.e., predictive for PFS and OS [108].
18
FDG-PET is recommended before surgery of
patients with advanced disease considered for
neoadjuvant therapy, and as a baseline measure
before initiation of systemic therapy in this group
of patients [36].
18
FDG-PET images are thus reli-
able surrogate markers of response to imatinib
and outcome [33]. Recent data confirmed that a
single PET performed after one month on suni-
tinib was also predictive of patient outcome [109].
Commercial hybrid PET/CT systems are avail-
able and have been shown to be useful in GIST
[110]. ESMO guidelines recommended
18
FDG-
PET only if early detection of tumour response to
imatinib treatment is required for the purpose of
planning surgery or response evaluation is equiv-
ocal [34]. Swiss guidelines recommend perform-
ing
18
FDG-PET in non-resectable GIST and as a
baseline measure before initiation of neoadjuvant
TKI therapy and one month after treatment start
[36].
New CHOI criteria vs conventional RECIST criteria
It is essential for the management of advanced
GIST that response to treatment be determined
accurately and early. The conventional Response
Evaluation Criteria in Solid Tumours (RECIST)
[111] and SWOG criteria [112] are based on tu-
mour size and are limited in assessing responses in
the era of TKI, because of several particular re-
sponse characteristics of GIST. GIST responding
to TKI-therapy, for example, may increase in size
due to fluid-volume expansion. Tumour vascular-
ity and density, which also play a role, are not cap-
tured by these criteria. Overall clinical benefit is
also underestimated by RECIST and SWOG cri-
teria as they ignore stable disease as response. To
address these shortcomings, modified CT imag-
ing criteria have been proposed that are based on
changes in tumour size and density (table 5) [113,
114]. These “Choi criteria” are sensitive and spe-
cific for assessing tumour response to TKI. They
predicted maximum lesional standardised uptake
values (SUVmax) and time to progression by a
more than 10% decrease in tumour size or a more
than 15% decrease in tumour density (as meas-
ured by Hounsfield Units). Sensitivity and speci-
ficity for identifying responders by
18
FDG-PET
were 97% and 100% respectively. Good and poor
18
FDG-PET responders could be significantly
differentiated by excellent prediction of TTP (p =
0.0002). A significant difference in disease-specific
survival was also detected after 60 months of ima-
tinib treatment (p = 0.04) [115]. The accuracy of
the “Choi criteria” may be compromised, how-
ever, by the presence of haemorrhage, calcifica-
tion, and perforation of lesions.
RECIST definition [111] Response «Choi» definition [113]
Disappearance of all lesions Complete (CR) Disappearance of all lesions
No new lesions No new lesions
30% decrease in size Partial (PR) ≥10% decrease in size OR
≥15% decrease in density (HU) on CT
No new lesions
No further increase No obvious progression of non-measurable disease
Does not meet criteria for partial Stable disease Does not meet criteria for complete response, partial response, or progression
response or progression (SD) No symptomatic deterioration attributed to tumour progression
20% increase in size Progression ≥10% increase of tumour size
AND (PD) AND does not meet criteria of PR by tumour density (HU) on CT
criteria for CR, PR or SD not New lesions
met before increased disease New intratumoral nodules or increase in size of existing intratumoral nodules
Table 5
RECIST and modified
CT response evalua-
tion criteria [111, 113].
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Future directions
Other candidate compounds for second- or
third-line therapy of imatinib-refractory GIST
are being tested [116, 117], e.g., the kinase in-
hibitors nilotinib [118], dasatinib [119], sorafenib
[120], masatinib [121], vatalanib [122], cediranib
[123], motesanib [124, 125], the PKC inhibitor
PKC412 [118], the rapamycin target protein
(FRAP1 or mTOR) inhibitor everolimus [126],
and the heat shock protein 90 (HSP90) inhibitor
IPI-504 [127]. Some of these substances may be
effective through their antiangiogenic effect, e.g.,
sorafenib, cediranib, motesanib and everolimus, as
well as sunitinib.
Economic considerations
Although efficacy and safety are the most im-
portant conditions for approval of new therapies,
the financial impact on a healthcare system must
also be assessed. Currently, two full reports on the
cost-effectiveness of imatinib in GIST are avail-
able: a very recent assessment from a US society
perspective based on a median of 52 months’ fol-
low-up data [128] and a health technology assess-
ment of the UK National Health Service from
2005 based on a median of 25 months’ follow-up
data [129]. Based on the more robust survival pro-
jections (5.8 years life expectancy with imatinib
therapy compared to 3.1 years without imatinib),
the US assessment yielded a cost-effectiveness
ratio of $38,723 per QALY. Cost-effectiveness in
the report of the UK NHS was in the range of
£21,404–33,976 per QALY, yet both figures are
within the range considered as societal willing-
ness to pay for a medical treatment (<$100,000 or
<£35,000 per QALY) [130, 131].A recent third in-
vestigation in Canada also concluded that ima-
tinib treatment is cost-effective. The annual in-
cremental cost-effectiveness ratio was established
at $15,882 per median life year gained and
$23,603 per median year of PFS [132].
Conclusion
Recent advances in molecular pathology, im-
aging techniques, surgical procedures, and sys-
temic drug therapy with tyrosine kinase inhibitors
(TKIs) have augmented the available options for
diagnosis and treatment of GIST. Most notably,
the introduction of imatinib therapy has signifi-
cantly improved clinical outcomes of patients with
advanced and metastatic GIST, nowadays also in
adjuvant and neoadjuvant settings. Diagnosis of
GIST is based on the histological and immuno-
histochemical presentation. Molecular typing
(mutational analysis) of tumour tissue can aid in
assessing prognosis and optimising drug therapy.
Conventional (CT scan) and novel imaging tech-
niques (functional PET) are valuable tools for dis-
ease staging and monitoring tumour size and
location during therapy. Complete gross surgical
resection with negative microscopic margins re-
mains the mainstay treatment of localised re-
sectable GIST. High risk patients with recurrent
GIST after complete resection, in particular those
with larger tumours, could profit from adjuvant
imatinib therapy. Neoadjuvant (preoperative)
therapy with imatinib is a promising new option
currently tested in clinical trials. Advanced, non-
resectable and/or metastatic GIST is safely and
continuously treated with imatinib at 400 mg
daily, with the option of dose escalation to 800 mg
daily on disease progression or in the cases with
exon 9 mutations. In salvage cases, surgery or
novel compounds such as sunitinib may be indi-
cated.
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